Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Hematuria is the presence of blood in a person's urine. There are several causes of blood in the urine, such as urinary tract infections, kidney or bladder stones, kidney infections, kidney disease, cancer, an enlarged prostate, kidney damage, and kidney disease to advances in the treatment of the disease. The antibiotics prescribed for treatment depend on the part of the tract being treated. However advances in the route of administration and the different concentrations of drugs make it possible to prevent the spread of disease or infection at the cellular and molecular level. If there are enough red cells the urine can become bright red, pink or brown colored. However the urine appears completely normal because there is not enough blood to cause a color change.
The major factors driving the growth of hematuria treatment market in the North America is due to growing cases of hematuria which create an opportunity for the pharma companies for novel therapy and promising pipeline drugs, huge investment in research and development are the factors responsible for the growth of this market. Huge investment in research and development are the factors responsible for the growth of this market. The increasing geriatric population is expected to increase the patient pool which in turn is projected to propel the global hematuria treatment market in the forecast period.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 360 degree analysis of micro and macro-economic factors on the North America hematuria treatment market. In addition, complete analysis of changes on the North America hematuria treatment market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on North America economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 pandemic had a positive impact on the North America hematuria treatment market as the strong and heavy dosage of medications used for the treatment of coronavirus infection has adverse effect on the patient’s kidney that led to increase in the development of various drugs and medication for the treatment.
North America Hematuria Treatment Market- Segmental Overview
The hematuria treatment market comprises of different market segment like type, indication, treatment, end user and country.
The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Macroscopic hematuria is visible blood in the urine causing it to be discoloured pink, red, brownish-red or tea-coloured. Gross hematuria is another term for visible blood in the urine. Whereas the microscopic hematuria cannot be seen in the urine as the red blood cells present in the urine are small and are visible only under the microscope. In idiopathic hematuria there is no specific cause for blood to be found in the urine as it is hereditary and also where there is no family history of kidney failure there is no specific treatment required to treat the idiopathic hematuria.
The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. Some of the main symptoms and causes can be seen in case of hematuria disease is inflammation of the kidney, urethra, bladder, or prostate in men, Abnormal structures in the urinary tract, Inherited diseases like polycystic kidney disease, sickle cell disease, or hemophilia, mineral imbalances in the urine. However in most of the cases hematuria is caused due to urinary tract or kidney infection.
The hematuria treatment market includes different treatments such as drugs, therapies. In adults microscopic hematuria is most commonly diagnosed. The adults diagnosed with microscopic hematuria with normal blood pressure and kidney function are advised to check their urine over several months if still the presence of bold continues a kidney ultrasound may be performed. Urine is checked for the presence of protein and calcium and creatinine which a waste product found in the urine. Also blood test to determine kidney function and other tests may be performed. Also in some cases the antibiotics treatment is enough for the disease treatment
The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. In case of serious infections proper diagnosis and treatment for the hematuria disease is necessary. If hematuria is caused by an infection like a urinary tract infection hematuria is treated with antibiotics. Also the healthcare provider advice to undergo various test of urine after treating the patient with antibiotics to make sure that the infection has cleared. If no serious condition is causing hematuria, no treatment is needed in such cases. However increase in healthcare expenditure, complications in the treatment and the growing cases of hematuria treatment are boosting the growth of the hospital segment growth in the region.
The North America hematuria treatment market is studied for the following countries like United States, Canada and Mexico. Due to the early adoption of advanced medical technologies and continuous development by companies operating in the hematuria treatment market are propelling the growth of the market in the region. Owing to worldwide leaders in research and development activities, poor lifestyle such as alcohol consumption and increase in the number of cases of hematuria is fueling the growth of the market. Furthermore increases in treatment rates and the presence of well-established healthcare facilities are major factors influencing the demand for medications.
The key players in hematuria treatment market are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH and The Medicines Company among others.
September 2021: AstraZeneca collaborated with VaxEquity for the discovery, development, and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London.
September 2021: Merck announced its definitive agreement to acquire Acceleron. Following the purchase of shares in the tender offer, Acceleron will become a subsidiary of Merck.
August 2021: Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for anticancer treatments.
June 2021: Eisai Co., Ltd. and Bristol-Myers Squibb Company entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody drug conjugate (ADC).
July 2021: GlaxoSmithKline plc. and Alector, announced a strategic global collaboration for the development and commercialization of two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels.
The report analyses the hematuria treatment market based on by type, indication, treatment, end user and country. The hematuria treatment is available in market according different type including macroscopic hematuria, microscopic hematuria, idiopathic hematuria, jogger’s hematuria. Macroscopic hematuria is visible blood in the urine causing it to be discoloured pink, red, brownish-red or tea-coloured. The hematuria treatment market has different indication like urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, menstruation. The hematuria treatment market includes different treatments such as drugs, therapies. In adults microscopic hematuria is most commonly diagnosed. The adults diagnosed with microscopic hematuria with normal blood pressure and kidney function are advised to check their urine over several months. The hematuria treatment market finds its major end user in hospitals, clinics, ambulatory surgical centers, others. In case of serious infections proper diagnosis and treatment for the hematuria disease is necessary. If hematuria is caused by an infection like a urinary tract infection hematuria is treated with antibiotics. The North America hematuria treatment market is studied for the following countries like United States, Canada and Mexico.
Why to buy this report
